Abstract:To compare the efficacy of chemotherapy alone, radiotherapy alone and combined-modality therapy in the treatment for early-stage Hodgkin's lymphoma (HL).From 1999 to 2002, totally 150 patients with stage I or II HL were treated in our hospital. They were stratified into several groups based on initial treatment strategy: chemotherapy alone (CT group, n = 22), radiotherapy alone (RT group, n = 18), combined-modality therapy (CMT group, n = 109) and surgical resection (SR group, n = 1). Chemotherapy regimens were mainly ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) and MOPP (mechlorethamine, vincristine, procarbazine and prednisone). Radiotherapy modes included involved field radiotherapy (IFRT), extended field radiotherapy (EFRT) and sub-total nodal irradiation (STNI).The pathological types included nodular sclerosis (NS, n = 84), mixed-cellularity (MC, n = 39), lymphocyte-predominant (LP, n = 23), lymphocyte-depleted (LD, n = 3) and nodular lymphocyte predominant Hodgkin's disease (NLPHD, n = 1). Of those, 72 were evaluble in terms of prognostic factors. No poor prognostic factor was found in 36.1% or 29.2% of the patients according to EORTC or GHSG criteria, respectively. There were 33 patients with complete response (CR), 109 with partial response (PR), 5 with stable disease (SD) and 3 with progressive disease (PD) after initial therapy. The median follow-up period was 71.5 months. The overall 7-yr survival rate was 89.3%, and treatment failure rate at 6 years was 18.8%. The response rate of CMT group was superior to that of CT group, and the patients with nodular sclerosis or mixed-cellularity type had significantly lower risk of treatment failure (P = 0.009 and 0.019, respectively). The multivariate analysis revealed that the treatment strategies affected the prognosis significantly. The risk of failure of chemotherapy alone was 2.52 times higher than that of combined-modality therapy (P = 0.004). No predictive factor affecting OS was identified by either univariate or multivariate analysis. The patients in CMT group suffered more adverse effects than those in either CT or RT groups, which mainly consisted of leucopenia, alopecia and gastrointestinal symptoms.Combined-modality therapy is more effective than chemotherapy alone or radiotherapy alone in the treatment for early stage Hodgkin's lymphoma. Though its acute adverse effects are more severe than that of chemotherapy or radiotherapy alone, it may reduce the risk of treatment failure.

Therapeutic effect of Matrine Glucose Injection combined with CHOP on non-Hodgkin's lymphoma

Clinical Efficacy of Compound Matrine Injection in Combination with GP Chemotherapy for Advanced Non-small Cell Lung Cancer

Short-Term Effect Of Combined Therapy With Jinlong Capsule ((Sic)) And Transcatheter Arterial Chemoembolization On Patients With Primary Hepatic Carcinoma And Its Influence On Serum Osteopontin Expression

Efficacy of Medroxyprogesterone Acetate Combined with Ondansetron on Preventing Vomiting Induced by Chemtherapy for Non-Small Cell Lung Cancer

A Clinical Study of Rituximab Combined with CHOP in Treatment of B Cell Non-Hodgkins Lymphoma

Therapeutic Effect of Chinese Medicinal Herbs Combined with Chemotherapy on Advanced Non-Small Cell Lung Cancer

Efficacy of Rituximab Combined with CHOP for B Cell Non-Hodgkin's Lymphoma

Clinical Efficacy of Combination of Rituximab Plus CHOP Scheme for Non-Hodgkin's Lymphoma

[Clinical Comparison of CHO Regimen Versus CHOP Regimen for Treatment of Patients with Intermediate-Grade Non-Hodgkin's Lymphoma].

[Meta Analysis of Compound Matrine Injection Combined with Cisplatin Chemotherapy for Advanced Gastric Cancer].

[Treatment Outcome Analysis of CTOP or CHOP Regimen in Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma Patients-Results of a Prospective, Open, Randomized, Multicenter Clinical Trial].

Matrine Enhances the Antitumor Efficacy of Chidamide in CTCL by Promoting Apoptosis

Effect of Gefitinib Combined with Compound Matrine Injection on Patients with Advanced Lung Cancer after Chemotherapy

Clinical Trial in the Treatment of Non-Hodgkin's Lymphoma's with Escalated CTOP Regimen

Matrine Promotes the Efficacy and Safety of Platinum-Based Doublet Chemotherapy for Advanced Non-Small Cell Lung Cancer.

Clinical Randomized Comparative Trial of ProMACE-CytaBOM Regimen and CHOP Regimen in Treating Non-Hodgkin's Lymphoma

[Clinical Analysis of Rituximab Combined with Chemotherapy in Treating Aggressive B-cell Non-Hodgkin's Lymphoma].

Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma]

[Comparison Between R-CHOP Regimen and CHOP Regimen in Treating Naive Diffuse Large B-cell Lymphoma in China--a Multi-Center Randomized Trail].

Clinical research of combined xiaoaiping injection with chemotherapy on advanced non-small cell lung cancer

Five-year Survival Analysis of Patients with Non-Hodgkin's Lymphoma Treated with Escalated CTOP Regimen